AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) � Form 4 insider transaction filing. SVP & Global Controller Jolanda Howe reported three transactions between 1�3 July 2025.

  • 1 Jul 2025: 1,041 restricted stock units (RSUs) converted into an equal number of common shares (Transaction Code M). Post-conversion ownership temporarily rose to 3,467 shares.
  • 2 Jul 2025: 564 shares sold at $48.25 (Code S) to cover tax-withholding obligations tied to the RSU vesting.
  • 3 Jul 2025: 477 shares sold at $49.08 under a pre-existing Rule 10b5-1 plan adopted 16 Dec 2024.

Following these actions, Howe’s direct beneficial ownership declined from 3,467 to 2,426 common shares. All 1,041 RSUs from the reported award are now fully settled, leaving no outstanding derivative securities.

The RSU grant vests in three equal annual installments that began on 1 Jul 2023. All reported transactions were executed by a single insider; no joint filings were made.

Mirum Pharmaceuticals, Inc. (MIRM) � Comunicazione di operazioni interne Form 4. La SVP e Global Controller Jolanda Howe ha segnalato tre operazioni avvenute tra il 1 e il 3 luglio 2025.

  • 1 luglio 2025: 1.041 unità di azioni vincolate (RSU) convertite in un pari numero di azioni ordinarie (Codice transazione M). Dopo la conversione, la proprietà è temporaneamente salita a 3.467 azioni.
  • 2 luglio 2025: Vendute 564 azioni a 48,25 $ (Codice S) per coprire le imposte dovute dal vesting delle RSU.
  • 3 luglio 2025: Vendute 477 azioni a 49,08 $ nell’ambito di un piano Rule 10b5-1 preesistente adottato il 16 dicembre 2024.

Dopo queste operazioni, la proprietà diretta di Howe è diminuita da 3.467 a 2.426 azioni ordinarie. Tutte le 1.041 RSU assegnate sono ora completamente liquidate, senza titoli derivati residui.

La concessione delle RSU si matura in tre rate annuali uguali a partire dal 1 luglio 2023. Tutte le operazioni segnalate sono state effettuate da un unico insider; non sono state presentate comunicazioni congiunte.

Mirum Pharmaceuticals, Inc. (MIRM) � Presentación de transacciones internas Formulario 4. La SVP y Controladora Global Jolanda Howe reportó tres transacciones realizadas entre el 1 y el 3 de julio de 2025.

  • 1 de julio de 2025: 1,041 unidades restringidas de acciones (RSU) convertidas en igual número de acciones comunes (Código de transacción M). Tras la conversión, la propiedad aumentó temporalmente a 3,467 acciones.
  • 2 de julio de 2025: Venta de 564 acciones a $48.25 (Código S) para cubrir obligaciones fiscales relacionadas con la adquisición de las RSU.
  • 3 de julio de 2025: Venta de 477 acciones a $49.08 bajo un plan Rule 10b5-1 preexistente adoptado el 16 de diciembre de 2024.

Después de estas operaciones, la propiedad directa de Howe disminuyó de 3,467 a 2,426 acciones comunes. Todas las 1,041 RSU del otorgamiento reportado están completamente liquidadas, sin valores derivados pendientes.

La concesión de las RSU se consolida en tres cuotas anuales iguales que comenzaron el 1 de julio de 2023. Todas las transacciones reportadas fueron realizadas por un solo insider; no se presentaron informes conjuntos.

Mirum Pharmaceuticals, Inc. (MIRM) â€� ë‚´ë¶€ìž� 거래 ì‹ ê³ ì„� Form 4 제출. SVP ê²� 글로벌 컨트롤러 Jolanda Howeê°€ 2025ë…� 7ì›� 1ì¼ë¶€í„� 3ì¼ê¹Œì§€ ì„� ê±´ì˜ ê±°ëž˜ë¥� 보고했습니다.

  • 2025ë…� 7ì›� 1ì�: 1,041ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ê°€ ë™ì¼ 수량ì� 보통주로 전환ë�(거래 코드 M). 전환 í›� 보유 ì£¼ì‹ ìˆ˜ê°€ ì¼ì‹œì ìœ¼ë¡� 3,467주로 ì¦ê°€í•�.
  • 2025ë…� 7ì›� 2ì�: RSU ë² ìŠ¤íŒ…ì— ë”°ë¥¸ 세금 ì›ì²œì§•수 ì˜ë¬´ë¥� 충당하기 위해 564주를 $48.25ì—� 매ë„(코드 S).
  • 2025ë…� 7ì›� 3ì�: 2024ë…� 12ì›� 16ì¼ì— 채íƒë� 기존 Rule 10b5-1 계íšì—� ë”°ë¼ 477주를 $49.08ì—� 매ë„.

ì� 거래ë“� ì´í›„ Howeì� ì§ì ‘ 보유 주ì‹ì€ 3,467주ì—ì„� 2,426ì£�ë¡� ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ë³´ê³ ë� 1,041 RSUëŠ� ëª¨ë‘ ì™„ì „íž� ì •ì‚°ë˜ì–´ 미결 íŒŒìƒ ì¦ê¶Œì� 없습니다.

RSU 부여는 2023ë…� 7ì›� 1ì¼ë¶€í„� 시작하여 3ë…„ê°„ 매년 ë™ì¼í•� 비율ë¡� 베스팅ë©ë‹ˆë‹¤. ë³´ê³ ë� 모든 거래ëŠ� ë‹¨ì¼ ë‚´ë¶€ìžê°€ 수행했으ë©� ê³µë™ ì‹ ê³ ëŠ� 없었습니ë‹�.

Mirum Pharmaceuticals, Inc. (MIRM) � Déclaration des transactions d’initiés Formulaire 4. La SVP et Contrôleuse Globale Jolanda Howe a déclaré trois transactions réalisées entre le 1er et le 3 juillet 2025.

  • 1er juillet 2025 : 1 041 unités d’actions restreintes (RSU) converties en un nombre égal d’actions ordinaires (Code transaction M). Après conversion, la détention a temporairement augmenté à 3 467 actions.
  • 2 juillet 2025 : 564 actions vendues à 48,25 $ (Code S) pour couvrir les obligations fiscales liées à l’acquisition des RSU.
  • 3 juillet 2025 : 477 actions vendues à 49,08 $ dans le cadre d’un plan Rule 10b5-1 préexistant adopté le 16 décembre 2024.

À la suite de ces opérations, la détention directe de Howe a diminué de 3 467 à 2 426 actions ordinaires. Les 1 041 RSU attribuées sont désormais entièrement réglées, sans titres dérivés en suspens.

La subvention des RSU se libère en trois versements annuels égaux débutant le 1er juillet 2023. Toutes les transactions déclarées ont été effectuées par un seul initié; aucune déclaration conjointe n’a été faite.

Mirum Pharmaceuticals, Inc. (MIRM) � Form 4 Insider-Transaktionsmeldung. SVP & Global Controller Jolanda Howe meldete drei Transaktionen zwischen dem 1. und 3. Juli 2025.

  • 1. Juli 2025: 1.041 Restricted Stock Units (RSUs) wurden in die gleiche Anzahl von Stammaktien umgewandelt (Transaktionscode M). Nach der Umwandlung stieg der Besitz vorübergehend auf 3.467 Aktien.
  • 2. Juli 2025: 564 Aktien wurden zum Preis von 48,25 $ verkauft (Code S), um Steuerabzugsverpflichtungen im Zusammenhang mit dem RSU-Vesting zu decken.
  • 3. Juli 2025: 477 Aktien wurden zum Preis von 49,08 $ im Rahmen eines bestehenden Rule 10b5-1 Plans verkauft, der am 16. Dezember 2024 eingeführt wurde.

Nach diesen Transaktionen verringerte sich Howes direkter Besitz von 3.467 auf 2.426 Stammaktien. Alle 1.041 RSUs aus der gemeldeten Zuteilung sind nun vollständig abgegolten, es bestehen keine ausstehenden derivativen Wertpapiere mehr.

Die RSU-Zuteilung erfolgt in drei gleichen jährlichen Raten, beginnend am 1. Juli 2023. Alle gemeldeten Transaktionen wurden von einem einzelnen Insider durchgeführt; es wurden keine gemeinsamen Meldungen eingereicht.

Positive
  • RSU conversion adds 1,041 shares to insider’s equity before sales, demonstrating continued participation in the company’s long-term incentive program.
Negative
  • Full disposal of newly vested shares (1,041 in total) at an average of ~$48.64 reduces direct holdings to 2,426 shares.

Insights

TL;DR: Routine RSU vesting offset by tax-related and 10b5-1 sales; net ownership down to 2,426 shares—overall neutral signal.

The filing shows a standard RSU conversion (Code M) for 1,041 shares, immediately followed by sales that match the acquired amount. One sale covered withholding taxes, while the second was executed under a pre-scheduled Rule 10b5-1 plan, indicating no discretionary timing. Average sale price was roughly $48.64, providing an implied cash value of ~$50.7k. Because the insider retains 2,426 shares and the transactions appear administrative, the market impact is likely neutral. No information suggests strategic intent or changing outlook for MIRM.

Mirum Pharmaceuticals, Inc. (MIRM) � Comunicazione di operazioni interne Form 4. La SVP e Global Controller Jolanda Howe ha segnalato tre operazioni avvenute tra il 1 e il 3 luglio 2025.

  • 1 luglio 2025: 1.041 unità di azioni vincolate (RSU) convertite in un pari numero di azioni ordinarie (Codice transazione M). Dopo la conversione, la proprietà è temporaneamente salita a 3.467 azioni.
  • 2 luglio 2025: Vendute 564 azioni a 48,25 $ (Codice S) per coprire le imposte dovute dal vesting delle RSU.
  • 3 luglio 2025: Vendute 477 azioni a 49,08 $ nell’ambito di un piano Rule 10b5-1 preesistente adottato il 16 dicembre 2024.

Dopo queste operazioni, la proprietà diretta di Howe è diminuita da 3.467 a 2.426 azioni ordinarie. Tutte le 1.041 RSU assegnate sono ora completamente liquidate, senza titoli derivati residui.

La concessione delle RSU si matura in tre rate annuali uguali a partire dal 1 luglio 2023. Tutte le operazioni segnalate sono state effettuate da un unico insider; non sono state presentate comunicazioni congiunte.

Mirum Pharmaceuticals, Inc. (MIRM) � Presentación de transacciones internas Formulario 4. La SVP y Controladora Global Jolanda Howe reportó tres transacciones realizadas entre el 1 y el 3 de julio de 2025.

  • 1 de julio de 2025: 1,041 unidades restringidas de acciones (RSU) convertidas en igual número de acciones comunes (Código de transacción M). Tras la conversión, la propiedad aumentó temporalmente a 3,467 acciones.
  • 2 de julio de 2025: Venta de 564 acciones a $48.25 (Código S) para cubrir obligaciones fiscales relacionadas con la adquisición de las RSU.
  • 3 de julio de 2025: Venta de 477 acciones a $49.08 bajo un plan Rule 10b5-1 preexistente adoptado el 16 de diciembre de 2024.

Después de estas operaciones, la propiedad directa de Howe disminuyó de 3,467 a 2,426 acciones comunes. Todas las 1,041 RSU del otorgamiento reportado están completamente liquidadas, sin valores derivados pendientes.

La concesión de las RSU se consolida en tres cuotas anuales iguales que comenzaron el 1 de julio de 2023. Todas las transacciones reportadas fueron realizadas por un solo insider; no se presentaron informes conjuntos.

Mirum Pharmaceuticals, Inc. (MIRM) â€� ë‚´ë¶€ìž� 거래 ì‹ ê³ ì„� Form 4 제출. SVP ê²� 글로벌 컨트롤러 Jolanda Howeê°€ 2025ë…� 7ì›� 1ì¼ë¶€í„� 3ì¼ê¹Œì§€ ì„� ê±´ì˜ ê±°ëž˜ë¥� 보고했습니다.

  • 2025ë…� 7ì›� 1ì�: 1,041ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ê°€ ë™ì¼ 수량ì� 보통주로 전환ë�(거래 코드 M). 전환 í›� 보유 ì£¼ì‹ ìˆ˜ê°€ ì¼ì‹œì ìœ¼ë¡� 3,467주로 ì¦ê°€í•�.
  • 2025ë…� 7ì›� 2ì�: RSU ë² ìŠ¤íŒ…ì— ë”°ë¥¸ 세금 ì›ì²œì§•수 ì˜ë¬´ë¥� 충당하기 위해 564주를 $48.25ì—� 매ë„(코드 S).
  • 2025ë…� 7ì›� 3ì�: 2024ë…� 12ì›� 16ì¼ì— 채íƒë� 기존 Rule 10b5-1 계íšì—� ë”°ë¼ 477주를 $49.08ì—� 매ë„.

ì� 거래ë“� ì´í›„ Howeì� ì§ì ‘ 보유 주ì‹ì€ 3,467주ì—ì„� 2,426ì£�ë¡� ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ë³´ê³ ë� 1,041 RSUëŠ� ëª¨ë‘ ì™„ì „íž� ì •ì‚°ë˜ì–´ 미결 íŒŒìƒ ì¦ê¶Œì� 없습니다.

RSU 부여는 2023ë…� 7ì›� 1ì¼ë¶€í„� 시작하여 3ë…„ê°„ 매년 ë™ì¼í•� 비율ë¡� 베스팅ë©ë‹ˆë‹¤. ë³´ê³ ë� 모든 거래ëŠ� ë‹¨ì¼ ë‚´ë¶€ìžê°€ 수행했으ë©� ê³µë™ ì‹ ê³ ëŠ� 없었습니ë‹�.

Mirum Pharmaceuticals, Inc. (MIRM) � Déclaration des transactions d’initiés Formulaire 4. La SVP et Contrôleuse Globale Jolanda Howe a déclaré trois transactions réalisées entre le 1er et le 3 juillet 2025.

  • 1er juillet 2025 : 1 041 unités d’actions restreintes (RSU) converties en un nombre égal d’actions ordinaires (Code transaction M). Après conversion, la détention a temporairement augmenté à 3 467 actions.
  • 2 juillet 2025 : 564 actions vendues à 48,25 $ (Code S) pour couvrir les obligations fiscales liées à l’acquisition des RSU.
  • 3 juillet 2025 : 477 actions vendues à 49,08 $ dans le cadre d’un plan Rule 10b5-1 préexistant adopté le 16 décembre 2024.

À la suite de ces opérations, la détention directe de Howe a diminué de 3 467 à 2 426 actions ordinaires. Les 1 041 RSU attribuées sont désormais entièrement réglées, sans titres dérivés en suspens.

La subvention des RSU se libère en trois versements annuels égaux débutant le 1er juillet 2023. Toutes les transactions déclarées ont été effectuées par un seul initié; aucune déclaration conjointe n’a été faite.

Mirum Pharmaceuticals, Inc. (MIRM) � Form 4 Insider-Transaktionsmeldung. SVP & Global Controller Jolanda Howe meldete drei Transaktionen zwischen dem 1. und 3. Juli 2025.

  • 1. Juli 2025: 1.041 Restricted Stock Units (RSUs) wurden in die gleiche Anzahl von Stammaktien umgewandelt (Transaktionscode M). Nach der Umwandlung stieg der Besitz vorübergehend auf 3.467 Aktien.
  • 2. Juli 2025: 564 Aktien wurden zum Preis von 48,25 $ verkauft (Code S), um Steuerabzugsverpflichtungen im Zusammenhang mit dem RSU-Vesting zu decken.
  • 3. Juli 2025: 477 Aktien wurden zum Preis von 49,08 $ im Rahmen eines bestehenden Rule 10b5-1 Plans verkauft, der am 16. Dezember 2024 eingeführt wurde.

Nach diesen Transaktionen verringerte sich Howes direkter Besitz von 3.467 auf 2.426 Stammaktien. Alle 1.041 RSUs aus der gemeldeten Zuteilung sind nun vollständig abgegolten, es bestehen keine ausstehenden derivativen Wertpapiere mehr.

Die RSU-Zuteilung erfolgt in drei gleichen jährlichen Raten, beginnend am 1. Juli 2023. Alle gemeldeten Transaktionen wurden von einem einzelnen Insider durchgeführt; es wurden keine gemeinsamen Meldungen eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Howe Jolanda

(Last) (First) (Middle)
C/O MIRUM PHARMACEUTICALS, INC.
989 E HILLSDALE BLVD., SUITE 300

(Street)
FOSTER CITY CA 94404

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, GLOBAL CONTROLLER
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 M 1,041 A (1) 3,467 D
Common Stock 07/02/2025 S(2) 564 D $48.25 2,903 D
Common Stock 07/03/2025 S(3) 477 D $49.08 2,426 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 07/01/2025 M 1,041 (4) (4) Common Stock 1,041 $0 0 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
3. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 16, 2024.
4. The restricted stock units vest in a series of three successive equal annual installments beginning July 1, 2023.
/s/ Judit Ryvkin, Attorney-in-Fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who conducted the transactions reported in Mirum Pharmaceuticals� Form 4?

SVP & Global Controller Jolanda Howe was the sole reporting person.

How many shares were acquired through RSU vesting on July 1, 2025?

A total of 1,041 common shares were acquired via RSU conversion (Code M).

What prices were the insider sales executed at for MIRM stock?

Shares were sold at $48.25 on July 2 and $49.08 on July 3, 2025.

How many Mirum shares does the insider own after the reported transactions?

Post-transaction beneficial ownership stands at 2,426 common shares.

Were the sales discretionary or pre-planned?

The July 2 sale covered tax withholding; the July 3 sale was executed under a Rule 10b5-1 plan adopted on December 16, 2024.
Mirum Pharmaceuticals

NASDAQ:MIRM

MIRM Rankings

MIRM Latest News

MIRM Latest SEC Filings

MIRM Stock Data

2.43B
41.56M
2.16%
113.24%
13.52%
Biotechnology
Pharmaceutical Preparations
United States
FOSTER CITY